Eli Lilly Files 8-K on Financials and Debt

Ticker: LLY · Form: 8-K · Filed: 2025-02-06T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, debt, filing

TL;DR

Lilly dropped an 8-K detailing its financials and a bunch of debt notes maturing all the way out to 2061.

AI Summary

Eli Lilly and Company filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, detailing various debt instruments such as notes due in 2025, 2026, 2030, 2031, 2033, 2036, 2043, 2049, 2051, and 2061.

Why It Matters

This filing provides investors with an update on Eli Lilly's financial health and its various outstanding debt obligations, which are crucial for assessing the company's financial stability and future borrowing capacity.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate adverse events.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the results are not provided in the header information.

What is the total amount of debt being disclosed?

The provided text lists various debt instruments with different maturity dates (e.g., notes due June 1, 2025; June 2, 2026; etc.), but the principal amounts for these notes are not specified in this header.

Are there any new debt issuances or significant changes to existing debt?

The filing is an 8-K reporting on financial condition and exhibits, which typically includes information on existing debt, but the header does not specify if there are new issuances or changes.

What is the purpose of filing an 8-K on February 6, 2025?

The 8-K is filed to report on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits' as of February 6, 2025.

What industry does Eli Lilly & Co. operate in?

Eli Lilly & Co. operates in the 'Pharmaceutical Preparations' industry, with SIC code 2834.

From the Filing

0000059478-25-000037.txt : 20250206 0000059478-25-000037.hdr.sgml : 20250206 20250206070512 ACCESSION NUMBER: 0000059478-25-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250206 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 25595427 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 lly-20250206.htm 8-K lly-20250206 0000059478 false 0000059478 2025-02-06 2025-02-06 0000059478 us-gaap:CommonClassAMember 2025-02-06 2025-02-06 0000059478 lly:A718NotesDueJune12025Member 2025-02-06 2025-02-06 0000059478 lly:A1.625NotesDueJune22026Member 2025-02-06 2025-02-06 0000059478 lly:A2.125NotesDueJune32030Member 2025-02-06 2025-02-06 0000059478 lly:A625Notesdue2031Member 2025-02-06 2025-02-06 0000059478 lly:A500NotesDue2033Member 2025-02-06 2025-02-06 0000059478 lly:A6.77NotesDueJanuary12036Member 2025-02-06 2025-02-06 0000059478 lly:A1625NotesDue2043Member 2025-02-06 2025-02-06 0000059478 lly:A1.700Notesdue2049Member 2025-02-06 2025-02-06 0000059478 lly:A1125NotesDue2051Member 2025-02-06 2025-02-06 0000059478 lly:A1375NotesDue2061Member 2025-02-06 2025-02-06   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter)   Indiana   001-06351   35-0470950 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)     Lilly Corporate Center Indianapolis, Indiana 46285 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 317 ) 276-2000 Not Applicable (Former Name or Former Address, if Changed Since Last Report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2.): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (no par value) LLY New York Stock Exchange 7 1/8% Notes due 2025 LLY25 New York Stock Exchange 1.625% Notes due 2026 LLY26 New York Stock Exchange 2.125% Notes due 2030 LLY30 New York Stock Exchange 0.625% Notes due 2031 LLY31 New York Stock Exchange 0.500% Notes due 2033 LLY33 New York Stock Exchange 6.77% Notes due 2036 LLY36 New York Stock Exchange 1.625% Notes due 2043 LLY43 New York Stock Exchange 1.700% Notes due 2049 LLY49A New York Stock Exchange 1.125% Notes due 2051 LLY51 New York Stock Exchange 1.375% Notes due 2061 LLY61 New York Stock Exchange Indicate

View on Read The Filing